Kura Oncology (NASDAQ:KURA) Price Target Cut to $25.00 by Analysts at Mizuho

Kura Oncology (NASDAQ:KURA) had its target price dropped by investment analysts at Mizuho from $30.00 to $25.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price objective suggests a potential upside of 212.50% from the company’s previous close.

Several other equities research analysts have also recently commented on the company. Barclays reissued an “overweight” rating and issued a $28.00 target price (up from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. Wall Street Zen cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. Finally, Leerink Partners set a $20.00 target price on shares of Kura Oncology and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.86.

Kura Oncology Price Performance

NASDAQ:KURA traded down $0.32 during mid-day trading on Tuesday, reaching $8.00. 512,009 shares of the company were exchanged, compared to its average volume of 1,468,971. The company has a quick ratio of 6.05, a current ratio of 6.06 and a debt-to-equity ratio of 0.06. The stock has a market cap of $706.64 million, a PE ratio of -2.52 and a beta of 0.22. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $12.49. The company has a fifty day moving average of $8.49 and a 200 day moving average of $9.49.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, March 5th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%.The company had revenue of $17.34 million for the quarter, compared to analyst estimates of $34.71 million. On average, research analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling

In other Kura Oncology news, insider Teresa Brophy Bair sold 11,208 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $94,819.68. Following the transaction, the insider owned 226,931 shares in the company, valued at approximately $1,919,836.26. This trade represents a 4.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian T. Powl sold 6,414 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $54,262.44. Following the transaction, the insider owned 183,275 shares of the company’s stock, valued at $1,550,506.50. The trade was a 3.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 36,068 shares of company stock worth $305,135. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently bought and sold shares of KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Kura Oncology by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after acquiring an additional 2,977 shares in the last quarter. Strs Ohio acquired a new position in Kura Oncology in the 1st quarter worth $143,000. Geode Capital Management LLC boosted its stake in Kura Oncology by 11.7% in the 2nd quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company’s stock worth $11,623,000 after purchasing an additional 211,470 shares during the period. Creative Planning increased its holdings in Kura Oncology by 102.5% during the 2nd quarter. Creative Planning now owns 136,259 shares of the company’s stock worth $786,000 after purchasing an additional 68,959 shares in the last quarter. Finally, Swiss National Bank increased its holdings in Kura Oncology by 29.6% during the 2nd quarter. Swiss National Bank now owns 115,700 shares of the company’s stock worth $668,000 after purchasing an additional 26,400 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.